Stock Events

Stock Events

Percheron Therapeutics 

$0
7
-$0-8.2% Monday 20:00

Statistics

Day High
0.01
Day Low
0.01
52W High
0.02
52W Low
0
Volume
40,000
Avg. Volume
2,229
Mkt Cap
4.99M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jul 21
$0.09
Nov 20
$0.04
Jul 20
$0.07
Nov 19
$0.03
Jul 19
$0.06
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

26FebExpected
Q2 2024
Q4 2024
Q2 2025
Q4 2025
-0.01
-0.01
-0
-0
Expected EPS
N/A
Actual EPS
-0.00188498125

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-19.29MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PERCF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a key competitor in the cystic fibrosis market, directly competing with Percheron Therapeutics' treatments in this area.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes in multiple therapeutic areas including immunology and oncology, overlapping with Percheron's research and drug development efforts.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is involved in biopharmaceuticals targeting genetic disorders, directly competing with Percheron's gene therapy projects.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics in areas like oncology and cardiovascular disease, which are also interest areas for Percheron Therapeutics.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences operates in the field of antiviral drugs, including treatments for HIV, hepatitis B, hepatitis C, and influenza, competing with Percheron's antiviral programs.
Biogen
BIIB
Mkt Cap22.63B
Biogen's focus on neurological diseases and innovative therapies places it in direct competition with Percheron's neurological drug development.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical targets rare genetic diseases, a field where Percheron is also actively developing treatments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals works on RNAi therapeutics, competing with Percheron's similar efforts in gene silencing technologies.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments in areas where Percheron Therapeutics is also active, such as cardiovascular, oncology, and neurology.

About

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also develops HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed Phase I clinical trial to targer v-domain immunoglobulin suppressor of T-cell activation and cancer cells. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Show more...
CEO
Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA
Country
AU
ISIN
AU0000317281

Listings

AU
AU
PER.AU
F
DE
AWY0.F
OTC Link
US
PERCF

0 Comments

Share your thoughts

FAQ

What is Percheron Therapeutics stock price today?▼
The current price of PERCF is $0 USD — it has decreased by -8.2% in the past 24 hours. Watch Percheron Therapeutics stock price performance more closely on the chart.
What is Percheron Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Percheron Therapeutics stocks are traded under the ticker PERCF.
What is Percheron Therapeutics market cap?▼
Today Percheron Therapeutics has the market capitalization of 4.99M
When is the next Percheron Therapeutics earnings date?▼
Percheron Therapeutics is going to release the next earnings report on September 02, 2026.
What were Percheron Therapeutics earnings last quarter?▼
PERCF earnings for the last quarter are -0 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Percheron Therapeutics revenue for the last year?▼
Percheron Therapeutics revenue for the last year amounts to 0 USD.
What is Percheron Therapeutics net income for the last year?▼
PERCF net income for the last year is -19.29M USD.
When did Percheron Therapeutics complete a stock split?▼
The last stock split for Percheron Therapeutics was on May 13, 2025 with a ratio of 11:10.
Where is Percheron Therapeutics headquartered?▼
Percheron Therapeutics is headquartered in Melbourne, AU.